Lili Chen's Colleagues at IASO BioTherapeutics
Lili Chen's Contact Details
IASO BioTherapeutics
Lili Chen's Company Details
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, as well as IASO's leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM), which was granted Breakthrough Therapeutic Designation by China's National Medical Products Administration (NMPA) in February 2021. In addition. The company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021. For more information on IASO Bio, please visit www.iasobio.com.